Pharmaceuticals - Community Register


Community list of not active orphan medicinal products


Product information


EU orphan designation number: EU/3/00/014
Active ingredient: Iloprost
Indication: Treatment of primary and of the following forms of secondary pulmonary hypertension: connective tissue disease pulmonary hypertension, drug-induced pulmonary hypertension, portopulmonary hypertension, pulmonary hypertension associated with congenital heart disease, chronic thromboembolic pulmonary hypertension
Sponsor: Bayer Pharma AG
D-13342 Berlin, Deutschland
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Ventavis on 16/09/2003 with the number EU/1/03/255

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
30/01/2001 Orphan designation EMEA/OD/009/00 (2000)4251 of 29/12/2000
26/02/2009 Change of name and/or address of sponsor
21/10/2011 Change of name and/or address of sponsor
18/09/2013 Removal of orphan designation from Community Register